Telix Pharmaceuticals Limited (ASX: TLX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 7.68B |
| Revenue (ttm) | 645.68M |
| Net Income (ttm) | 49.19M |
| Shares Out | 334.68M |
| EPS (ttm) | 0.15 |
| PE Ratio | 156.10 |
| Forward PE | 90.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,070,803 |
| Open | 22.97 |
| Previous Close | 22.96 |
| Day's Range | 22.03 - 23.22 |
| 52-Week Range | 9.06 - 23.99 |
| Beta | 2.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 20, 2025 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o... [Read more]
Financial Performance
Financial StatementsNews
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
MELBOURNE, Australia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new asset...
Telix ADSs Commence Trading on Nasdaq
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced tr...
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
MELBOURNE, Australia and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and ...
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & ...
Telix Pharmaceuticals: Strong Momentum Presents Opportunity
Telix Pharmaceuticals leverages a novel theranostic approach, offering a unique risk-reward model in the challenging biotech climate. Find out why TLPPF stock is a Buy.
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
MELBOURNE, Australia, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Me...
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
MELBOURNE, Australia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma1, which has the mission of expanding g...
Telix Files Form 20-F Registration Statement for Nasdaq ADS
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registrati...
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
MELBOURNE, Australia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter...
Health Canada Approves Label Expansion for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the p...
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharm...
Focus on supply chain and manufacturing in expansion plans: Telix Pharma CEO
Christian Behrenbruch, CEO of Telix Pharmaceuticals says the short shelf life of the company's key products means supply chains management is crucial for product distribution.
Telix Pharmaceuticals Limited (TLPPF) Q2 2024 Earnings Call Transcript
Telix Pharmaceuticals Limited (OTCPK:TLPPF) Q2 2024 Earnings Conference Call August 22, 2024 7:00 PM ETCompany ParticipantsKyahn Williamson - Senior Vice...
Focus on supply chain and manufacturing in expansion plans: Telix Pharma CEO
Christian Behrenbruch, CEO of Telix Pharmaceuticals says the short shelf life of the company's key products means supply chains management is crucial for product distribution.
Telix Pharmaceuticals Limited 2024 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Telix Pharmaceuticals Limited in conjunction with their 2024 Q2 earnings call.
Telix Pharmaceuticals reports 1H results; reaffirms FY24 outlook
Australia's Telix Pharma to raise $398 mln in debt to fund cancer therapy
Telix Pharmaceuticals aims to raise A$600 million ($397.5 million) via the issue of convertible notes to fund key trials for its kidney and brain cancer therapy programs, the biopharmaceutical company...
Telix Pharma Stock: Prostate Cancer Treatments Could Lead To Increased Value
Telix Pharma's product revenues in full-year 2023 were $502.5 million, an increase of 214% from 2022. Check out why I rate TLX stock a buy.
Telix Pharma pulls U.S. IPO citing market conditions
Telix Announces Launch of Proposed Initial Public Offering in the United States
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Of...
Revenue Stage Telix Pharmaceuticals Seeks $100 Million U.S. IPO
Telix Pharmaceuticals Limited has filed for a $100 million IPO to raise funds for its product pipeline, although the final figure may be higher. The company is a commercial-stage biopharma firm focuse...
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
MELBOURNE, Australia, May 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has filed a registration statement on Form F-1 (Registration...
Telix Pharmaceuticals reports Q1 results
Telix Pharmaceuticals reports Q1 revenue of $114.9M, a YoY increase of 18.3%.
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhance...
Telix Pharmaceuticals Ltd Grand Pharma Investor Webinar Transcript
Telix Pharmaceuticals Ltd Grand Pharma Investor Webinar Transcript